Skip to content

An Imaging and Cognition Study of Positive Valence Systems in Psychotic Syndromes

An Imaging and Cognition Study of Positive Valence Systems in Psychotic Syndromes - Brain Function of Individuals with Psychotic Disorders and Bipolar Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON54698
Enrollment
500
Registered
2020-02-18
Start date
2020-12-21
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: For patients: 1. Diagnosis of a psychotic disorder or bipolar disorder For all participants: 1. In case of participants from the GROUP or Bipolar Genetics study; provided past consent to be re-contacted for future studies. 2. Give written informed consent for the current study 3. Age 18 years or older 4. First degree family members of the included patients can participate, irrespective of having a psychiatric diagnosis or not. 5. Controls subjects must not have an affective or non-affective diagnosis, nor in their first-degree family members.

Exclusion criteria

Exclusion criteria: - No demonstration of adequate understanding of the purpose, procedures, risks, benefits, emergency contacts, and payment issues. - Unable to give consent to all aspects of the study. - Ferrous objects in or around the body (e.g. braces, tattoos, piercings, metal fragments; small braces are allowed - Pacemaker or other stimulatory devices/leads that are not temporarily removable from the body without health hazards - Claustrophobia - History of closed head injury - History of neurological illness or endocrine dysfunction - Neurological abnormalities as well as structural brain abnormalities that may interfere with the measurements, identified through neurodiagnostic evaluation

Design outcomes

Primary

MeasureTime frame
Estimates of brain activation during task performance.

Secondary

MeasureTime frame
Performance on the 3 PVS tasks, answers to questions (collected via self-report and interviews) on current demographics, clinical situation, motivational behaviour, and personality.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)